Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2021-07-13 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding abnormal stock price fluctuations over three trading days in July 2021. It includes details about the stock price increase, company self-inspection results, confirmation of no undisclosed material information, and risk warnings to investors. The document does not contain financial statements, management discussion, or detailed financial data. It is a regulatory announcement about stock trading behavior and compliance with stock exchange rules, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-07-13 Chinese
普华永道中天会计师事务所（特殊普通合伙）关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的第二轮审核问询函的回复（修订稿）
Regulatory Filings Classification · 95% confidence The document is a detailed response to regulatory inquiries regarding the use of IPO raised funds, clinical research progress, and project implementation risks. It discusses the company's fundraising, clinical trial stages, and project necessity and predictability. The content is technical, focused on clinical trial progress, funding usage, and regulatory compliance, typical of a regulatory filing or inquiry response. There is no indication that this is an annual report, earnings release, or management discussion. The document is not a simple announcement or a certification letter but a substantive regulatory response with detailed financial and operational data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2021-06-25 Chinese
神州细胞关于更新《关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的第二轮审核问询函》回复的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding updates to their responses to a second round of review inquiries from the Shanghai Stock Exchange about a specific share issuance application. It mentions the company's ongoing process of issuing shares to specific investors, the regulatory review by the Shanghai Stock Exchange and the China Securities Regulatory Commission, and the uncertainty of approval. The document is short (840 characters) and primarily serves as an update on the regulatory review process and disclosure obligations related to a capital raising event. It does not contain financial statements or detailed financial data, nor is it a full report or presentation. It is an announcement related to capital raising and regulatory review of a share issuance application, fitting best under Capital/Financing Update (CAP).
2021-06-25 Chinese
关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的第二轮审核问询函的回复报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed response report to a second round of inquiry from the Shanghai Stock Exchange regarding a company's application for a specific share issuance to targeted investors. It extensively discusses the use of IPO raised funds, progress of clinical research projects, and the necessity and feasibility of new fundraising projects. The content is focused on regulatory review and compliance related to a capital raising process, specifically an issuance of shares to specific investors. The document is lengthy (15,000 characters) and contains detailed financial and project progress data, indicating it is not a brief announcement but a substantive filing. The key phrases such as "向特定对象发行股票申请文件" (application for share issuance to specific investors), "募集资金" (raised funds), and detailed project and financial data align with a Capital/Financing Update. It is not an Annual Report, Earnings Release, or Management Report, nor is it a proxy or voting result announcement. It is a regulatory response document related to a capital raising process. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-06-25 Chinese
神州细胞关于回复《关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的第二轮审核问询函》的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding their response to a second round of review inquiry from the Shanghai Stock Exchange about their application for a private placement of shares. It mentions the review process, regulatory bodies involved (Shanghai Stock Exchange and China Securities Regulatory Commission), and the uncertainty of approval. The document is short (774 characters) and serves as a regulatory update on the financing process rather than the actual financing report or detailed financial data. It is not a full financial report, earnings release, or management discussion. It is an update on capital raising activities and regulatory review, fitting the Capital/Financing Update category.
2021-06-15 Chinese
关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的第二轮审核问询函的回复报告
Capital/Financing Update Classification · 95% confidence The document is a detailed response report to a second round of inquiry from the Shanghai Stock Exchange regarding a company's application for a private placement of shares. It extensively discusses the use of previously raised IPO funds, progress on clinical research projects, and the necessity and feasibility of new fundraising projects. The content is focused on regulatory review and compliance related to a capital raising process, specifically addressing questions from a securities exchange about fundraising and project implementation. The document is not a financial report like an annual or interim report, nor is it a call transcript or management report. It is not a simple announcement but a comprehensive reply to regulatory inquiries about a capital raising application. Therefore, the document fits best under the category of Capital/Financing Update (CAP), as it deals with fundraising activities and related regulatory responses.
2021-06-15 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.